MethA fibrosarcoma cells expressing membrane-bound forms of IL-2 enhance antitumor immunity

Journal of Microbiology and Biotechnology

Volumn 16, Issue 12, 2006, Pages 1919-1927

  Sonn, Chung Hee ^a   Yoon, Hee Ryung ^a   Seong, In Ock ^a   Chang, Mi Ra ^a   Kim, Yong Chan ^a   Kang, Han Chul ^b   Suh, Seok Cheol ^b   Kim, Young Sang ^a  

^a Chungnam National University   (South Korea)

^b National Institute of Animal Science   (South Korea)

Author keywords

Antitumor immunity; CTL; Direct priming; IL 2; Membrane bound form; Tumor vaccine

Indexed keywords

INTERLEUKIN 2; TUMOR NECROSIS FACTOR; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOGENICITY; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CHIMERA; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; IMMUNE RESPONSE; IN VITRO STUDY; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; SPLEEN CELL; TRANSGENIC MOUSE; TUMOR CELL; TUMOR IMMUNITY; WILD TYPE;

MUS; MUS MUSCULUS;

EID: 33846513969     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Assenmacher, M., A. Scheffold, J. Schmitz, J. A. Segura Checa, S. Miltenyi, and A. Radbruch. 1996. Specific expression of surface interferon-gamma on interferon-gamma producing T cells from mouse and man. Eur. J. Immunol. 26: 263-267.
2. Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17: 2105-2116.
3. Bai, X. F., J. Bender, J. Liu, H. Zhang, Y. Wang, O. Li, P. Du, P. Zheng, and Y. Liu. 2001. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J. Immunol. 167: 3936-3943.
4. Baskar, S., N. Nabavi, L. H. Glimcher, and S. Ostrand-Rosenberg. 1993. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J. Immunother. 14: 209-215.
5. Blankenstein, T., D. A. Rowley, and H. Schreiber. 1991. Cytokines and cancer: Experimental systems. Curr. Opin. Immunol. 3: 694-698.
6. Browning, J. L., A. Ngam-ek, P. Lawton, J. DeMarinis, R. Tizard, E. P. Chow, C. Hession, B. O'Brine-Greco, S. F. Foley, and C. F. Ware. 1993. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72: 847-856.
7. Chang, M. R., W. H. Lee, J. W. Choi, S. O. Park, S. G. Paik, and Y S. Kim. 2005. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2. Exp. Mol. Med. 37: 240-249.
8. Chen, B., T. M. Timiryasova, D. S. Gridley, M. L. Andres, R. Dutta-Roy, and I. Fodor. 2001. Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy. Cytokine 15: 305-314.
9. Chen, K., S. Braun, S. Lyman, Y. Fan, C. M. Traycoff, E. A. Wiebke, J. Gaddy, G. Sledge, H. E. Broxmeyer, and K. Cometta. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57: 3511-3516.
10. Cimino, A. M., P. Palaniswami, A. C. Kim, and P. Selvaraj. 2004. Cancer vaccine development: Protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol. Res. 29: 231-240.
11. Colombo, M. P., A. Modesti, G. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52: 4853-4857.
12. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543.
13. Dranoff, G. and R. C. Mulligan. 1995. Gene transfer as cancer therapy. Adv. Immunol. 58: 417-454.
14. el-Shami, K. M., E. Tzehoval, E. Vadai, M. Feldman, and L. Eisenbach. 1999. Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. J. Interferon Cytokine Res. 19: 1391-1401.
15. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403.
16. Gabrilovich, D. I., I. F. Ciemik, and D. P. Carbone. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170: 101-110.
17. Gansbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172: 1217-1224.
18. Hillman, G. G., P. Slos, Y. Wang, J. L. Wright, A. Layer, M. De Meyer, M. Yudelev, M. Che, and J. D. Forman. 2004. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Ther. 11: 61-72.
19. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
20. Jackaman, C., C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. Robinson, and D. J. Nelson. 2003. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J. Immunol. 171: 5051-5063.
21. Kammula, U. S., D. E. White, and S. A. Rosenberg. 1998. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83: 797-805.
22. Kim, E. J., D. J. Kim, H. Y. Hwang, J. S. Yoon, Y. Yoon, and K. H. Baek. 2004. High-level expression of recombinant human interleukin-2 in Chinese hamster ovary cells using the expression system containing transcription terminator. J. Microbiol. Biotechnol. 14: 810-815.
23. Kim, H. Y., J. O. Yang, and G. O. Ji. 2005. Effect of bifidobacteria on production of allergy-related cytokines from mouse spleen cells. J. Microbiol. Biotechnol. 15: 265-268.
24. Kim, Y. S., C. H. Sonn, S. G. Paik, and A. L. Bothwell. 2000. Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity. Gene Ther. 7: 837-843.
25. Kriegler, M., C. Perez, K. DeFay, I. Albert, and S. D. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45-53.
26. Kundig, T. M., M. F. Bachmann, C. DiPaolo, J. J. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, et al. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268: 1343-1347.
27. Kurt-Jones, E. A., W. Fiers, and J. S. Pober. 1987. Membrane interleukin 1 induction on human endothelial cells and dermal fibroblasts. J. Immunol. 139: 2317-2324.
28. Leonard, J. P., M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen, M. B. Atkins, J. A. Sosman, J. P. Dutcher, N. J. Vogelzang, and J. L. Ryan. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548.
29. Lollini, P. L. and G. Forni. 2003. Cancer immunoprevention: Tracking down persistent tumor antigens. Trends Immunol. 24: 62-66.
30. Lotze, M. T., Y. L. Matory, A. A. Rayner, S. E. Ettinghausen, J. T. Vetto, C. A. Seipp, and S. A. Rosenberg. 1986. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 2764-2772.
31. Lu, X., N. L. Kallinteris, J. Li, S. Wu, Y. Li, Z. Jiang, G. G. Hillman, J. V. Gulfo, R. E. Humphreys, and M. Xu. 2003. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol. Immunother. 52: 592-598.
32. Luo, L., A. I. Chapoval, D. B. Flies, G. Zhu, F. Hirano, S. Wang, J. S. Lau, H. Dong, K. Tamada, A. S. Flies, Y. Liu, and L. Chen. 2004. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J. Immunol. 173: 5445-5450.
33. Marr, R. A., C. L. Addison, D. Snider, W. J. Muller, J. Gauldie, and F. L. Graham. 1997. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther. 4: 1181-1188.
34. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795-1798.
35. Nanni, P., G. Forni, and P. L. Lollini. 1999. Cytokine gene therapy: Hopes and pitfalls. Ann. Oncol. 10: 261-266.
36. Nizard, P., D. A. Gross, A. Babon, A. Chenal, B. Beaumelle, K. Kosmatopoulos, and D. Gillet. 2003. Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice. J. Immunother. 26: 63-71.
37. Rivoltini, L., C. Gambacorti-Passerini, M. Squadrelli-Saraceno, M. I. Grosso, G. Cantu, R. Molinari, A. Orazi, and G. Parmiani. 1990. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res. 50: 5551-5557.
38. Salvadori, S., B. Gansbacher, A. M. Pizzimenti, and K. S. Zier. 1994. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J. Immunol. 153: 5176-5182.
39. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, and D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335: 271-274.
40. Soo, H. W., K. A. Lundeen, J. R. Kohrumel, N. L. Pham, S. W. Brostoff, R. M. Bartholomew, and D. J. Carlo. 1999. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J. Immunol. 162: 7343-7349.
41. Tepper, R. I. and J. J. Mule. 1994. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther 5: 153-164.
42. Tjuvajev, J., B. Gansbacher, R. Desai, B. Beattie, M. Kaplitt, C. Matei, J. Koutcher, E. Gilboa, and R. Blasberg. 1995. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55: 1902-1910.
43. Townsend, S. E. and J. P. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368-370.
44. Udaka, K., T. J. Tsomides, and H. N. Eisen. 1992. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69: 989-998.
45. Vesosky, B. and A. A. Hurwitz. 2003. Modulation of costimulation to enhance tumor immunity. Cancer Immunol. Immunother. 52: 663-669.
46. Wang, Y. C., L. Zhu, R. McHugh, K. W. Sell, and P. Selvaraj. 1995. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice. Eur. J. Immunol. 25: 1163-1167.
47. Wolkers, M. C., G. Stoetter, F. A. Vyth-Dreese, and T. N. Schumacher. 2001. Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses. J. Immunol. 167: 3577-3584.
48. Yang, J. C., L. Haworth, R. M. Sherry, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, S. M. Steinberg, H. X. Chen, and S. A. Rosenberg. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349: 427-434.
49. Yei, S., R. M. Bartholomew, P. Pezzoli, A. Gutierrez, E. Gouveia, D. Bassett, W. Soo Hoo, and D. J. Carlo. 2002. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: Generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Gene Ther. 9: 1302-1311.
50. Zier, K., B. Gansbacher, and S. Salvadori. 1996. Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy. Immunol. Today 17: 39-45.